MNC强势砸钱入场

艾美达医药咨询
Nov 17, 2025

2024年3月,美国FDA加速批准了Madrigal公司的Resmetirom(商品名:Rezdiffra),用于治疗伴有中度至晚期肝纤维化的非肝硬化代谢功能障碍相关脂肪性肝炎(MASH)患者。这一批准被行业视为“破冰时刻”,结束了该领域40余年无药可医的历史。紧随其后,MNC开始纷纷开始砸钱入场。2025年10月9日,诺和诺德宣布以最高52亿美元现金收购Akero Therapeutics,将其...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10